Larimar Therapeutics, Inc.
LRMR
$2.97
$0.113.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.41% | 4.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.34% | 71.34% | |||
| Operating Income | 0.34% | -71.34% | |||
| Income Before Tax | -1.59% | -85.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.59% | -85.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.59% | -85.97% | |||
| EBIT | 0.34% | -71.34% | |||
| EBITDA | 0.37% | -71.61% | |||
| EPS Basic | -1.35% | -85.96% | |||
| Normalized Basic EPS | -1.35% | -85.97% | |||
| EPS Diluted | -1.35% | -85.96% | |||
| Normalized Diluted EPS | -1.35% | -85.97% | |||
| Average Basic Shares Outstanding | 0.24% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.24% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||